Leap Therapeutics (Nasdaq: LPTX) is a cutting-edge brand that specializes in developing targeted cancer therapies. With a focus on immuno-oncology therapeutics, Leap is dedicated to transforming the landscape of cancer treatment. At the forefront of their product lineup is DKN-01, a monoclonal antibody that specifically targets the DKK1 protein.

This innovative therapy is being developed for patients with esophagogastric, gynecologic, and colorectal cancers. Additionally, Leap is advancing FL-301, a humanized monoclonal antibody that targets Claudin18. 2 and holds promise for patients with gastric and pancreatic cancer.

With a robust pipeline, Leap also has preclinical antibody programs targeting Claudin18. 2/CD137 and GDF15. Led by a team of accomplished professionals and backed by esteemed scientific advisory boards, Leap Therapeutics is committed to pioneering novel and impactful cancer treatments.

They are dedicated to improving the lives of patients and their families through cutting-edge research and development